News
NemaGen accepted into NIH I-Corps Program
Founder Mark Siracusa to speak at 24th TMS National Conference
NemaGen has received a Phase I SBIR from NCATS
To further support our drug development, NemaGen will be participating in an NIH I-Corps Program March-April 2023 to speak with various stakeholders to better understand their needs and validate our therapy's value. This program also comes with a $55,000 grant award. Thanks to NCATS for further supporting our efforts to develop therapies treating mastocytosis and other mast cell-related diseases!
NemaGen has received a Phase I SBIR from NCATS
Founder Mark Siracusa to speak at 24th TMS National Conference
NemaGen has received a Phase I SBIR from NCATS
NemaGen is honored and excited to announce that we were awarded an NIH Small Business Innovation Research grant. We would like to thank the NIH and NCATS for recognizing the significance and impact of our work focused on treating mastocytosis and other mast cell-related diseases.
Founder Mark Siracusa to speak at 24th TMS National Conference
Founder Mark Siracusa to speak at 24th TMS National Conference
Founder Mark Siracusa to speak at 24th TMS National Conference
Dr. Mark Siracusa spoke at the 24th conference which took place from October 13-20th, 2021
The 25th conference will take place in October 2022
Paper Published in Nature Immunology
NemaGen raises $1MM from Foundation Venture Capital Group
Founder Mark Siracusa to speak at 24th TMS National Conference
NemaGen's exciting findings have defined a previously unappreciated neuropeptide pathway that prevents unwanted lung inflammation. These studies were recently published in Nature Immunology.
NemaGen raises $1MM from Foundation Venture Capital Group
NemaGen raises $1MM from Foundation Venture Capital Group
NemaGen raises $1MM from Foundation Venture Capital Group
The Foundation Venture Capital Group has recently invested $1MM towards the development of NemaGen's technologies